Sequenom: Mishandling of results delays launch of Down Syndrome tests

Sequenom's (SQNM) announcement Wednesday after the close regarding its Down syndrome test highlights the risks facing pharmaceutical investors and pharmaceutical companies when developing, researching and testing drugs.

Sequenom said its SEQureDx Down syndrome test, which was scheduled for commercial launch in June, would be delayed because of employee mishandling of the data. Sequenom's stock, which closed Wednesday at $14.91, opened today at $3.30, plunging . As the stock plunges 75 percent this morning, it's interesting to get a glimpse into the world of pharmaceutical testing where integrity and accuracy matter no less than the validity of the science.